MedPath

The Effect of Transcranial Direct Current Stimulation on Fatigue Among Multiple Sclerosis Patients.Patients

Not Applicable
Not yet recruiting
Conditions
Multiple Sclerosis
Interventions
Device: a-tDCS
Registration Number
NCT05560139
Lead Sponsor
Assiut University
Brief Summary

This work is aimed to assess the long term effect of TDCS in fatigue management among MS patients

Detailed Description

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that is considered one of the most frequent causes of disability in the young adult.

Fatigue in MS may affect up to 80 % of the people with MS. It tends to persist over time once it appears. However, despite high frequency, fatigue remains poorly understood. Fatigue in MS is neither consistently linked to disease severity nor disease duration, although it is found to be worse in individuals with the secondary progressive subtype.

Fatigue is distinct from sleepiness, and fails to improve with adequate sleep. Multiple factors are thought to contribute to fatigue\[7 , 8\] with no specific biomarker or etiology yet confirmed.

A wide variety of therapies have been tested to reduce fatigue in MS, but unfortunately, none have been consistently effective. Transcranial direct current stimulation (tDCS) is a relatively recent therapeutic development that utilizes low-amplitude direct currents to induce changes in cortical excitability. Although various non-invasive neuromodulation technologies are available , tDCS has unique advantages compared to other stimulation methods such as its ease of use, lower cost, and greater safety and tolerability.

Small preliminary studies have observed that tDCS may be a promising treatment for MS fatigue, using sham-controlled crossover designs, with five tDCS sessions, using either a motor, sensory, or dorsolateral prefrontal cortex (DLPFC). Recently Chalah et al.\[12\] study demonstrated that DLPFC (left anodal) when compared the posterior parietal cortex led to the most fatigue specific improvements.

Thus, tDCS can reduce fatigue burden for people with MS, it may be possible to implement a tDCS therapy for symptomatic management of fatigue.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
36
Inclusion Criteria

Any adult patient will be fulfilling diagnostic criteria of Multiple sclerosis and could be providing consent for participation in the study, will be included in the study.

Exclusion Criteria
  • any patient showed this following condition will be excluded from the study;
  • Any MS patient had any contraindication condition to use TMS or TCDS (such as epilepsy, head trauma, metallic procedure, cerebral insult)
  • Any patient had infection or febrile condition.
  • Any patient had other co morbid neurological or psychiatric disorders or systemic disease.
  • Any patient refuses participation in study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sham groupa-tDCSThe sham group received ten sessions of sham stimulation for 20-minutes in each session.
experimental groupa-tDCSParticipants in the experimental groups received ten -sessions a-tDCS (1.5mA, 20minutes) anodal stimulation of left DLPC over two weeks duration (five sessions per week).
Primary Outcome Measures
NameTimeMethod
fatigue assessment scaleat post sessions, 1 month and 2 month post sessions

it is a acale filed by the patient and it consists of scale from 1 to 10

visual analogue scaleat post sessions, 1 month and 2 month post sessions

it is a scale from 0 to 10 to assess major fatigue

Secondary Outcome Measures
NameTimeMethod
changes in cortical excitability parameters at post 10th session compared to baseline measurements of cortical excitability parametersat post sessions, 1 month and 2 month post sessions

Detection of the relationship between cortical excitability changes{after 10th session) and changes in fatigue and HDS and QLoL changes..

© Copyright 2025. All Rights Reserved by MedPath